Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

– Company to host an Industry Forum to discuss its approach to protecting and preserving dystrophic muscle featuring key opinion leaders – BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The conference will take place at the Hilton Orlando in Orlando, FL from March 3-6, 2024. Details of the Edgewise presentations at MDA: Podium Presentation in Clinical Trial Updates Session Title: Functional and Muscle Damage Biomarker Changes Following Treatment with EDG-5506, a Fast Myosin Modulator, in Adults with Becker Muscular Dystrophy Dr. Phan’s presentation will include 12-month data from the ARCH trial of EDG-5506. Presenter: Han C. Phan, M.D., Head of Research & Principal Investigator, Pediatric Neurologist, Rare Disease Research, LLC Date: Wednesday, March 6, 2024, 11:15 – 11:30 am ET Scientific Posters Title: Comparison of Short- and Long-Term Proteomic Response to the Fast Skeletal Myosin Inhibitor, EDG-5506, in Becker Muscular Dystrophy (BMD) (Poster # M145) Title: North Star (NSAA and NSAD) Functional Assessments in Individuals with Becker Muscular Dystrophy (poster # M147) A companion poster presentation will be available for Dr. Phan’s presentation (poster # M146). Posters will be showcased during the Networking & Poster Reception in the Exhibit Hall on Monday, March 4, 2024, from 6 – 8 PM ET. The full MDA 2024 Conference program is available here: https://mdaconference.org. The Edgewise presentation and posters will be available on the Edgewise website when they are presented. Edgewise Industry Forum with Key Opinion Leaders On March 4, 2024, at 12 pm ET, Edgewise is sponsoring an Industry Forum, “Protecting and preserving dystrophic muscle: The balance between exercise and contraction-induced muscle injury.” The forum will feature presentations by leading neuromuscular disease experts, John Vissing, M.D., Ph.D., Professor of Neurology, Director Neuromuscular Clinic and Research Unit, Department of Neurology, University of Copenhagen, and Tanja Taivassalo, Ph.D., Associate Professor, Department of Physiology and Aging, University of Florida, as well as Edgewise Chief Medical Officer, Joanne Donovan, M.D., Ph.D. Only registered conference attendees can register for the symposium. About EDG-5506 for Duchenne and Becker Muscular Dystrophies EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Duchenne and Becker. EDG-5506 presents a novel mechanism of action designed to selectively limit the exaggerated muscle damage caused by the absence or loss of functional dystrophin. By minimizing the progressive muscle damage that leads to functional impairment, EDG-5506 has the potential to benefit a broad range of patients suffering from debilitating neuromuscular disorders. Its unique mechanism of action provides the potential to establish EDG-5506 as a foundational therapy in dystrophinopathies, either as a single agent therapy or in combination with available therapies and those in development. The Company is advancing EDG-5506 through the clinic including completing enrollment of a Phase 2 trial cohort, called CANYON, evaluating safety and effects on function and biomarkers of muscle damage in adult males with Becker, which has been expanded to include an additional 120 adult participants in a pivotal cohort called GRAND CANYON, which is currently enrolling. In Duchenne, the Company is advancing its Phase 2 clinical trials, LYNX, assessing safety, pharmacokinetics and biomarkers of muscle damage, and FOX, which includes children and adolescents previously treated with gene therapy. For more information on Edgewise’s clinical trials https://edgewisetx.com/clinical-trials. About Edgewise Therapeutics Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of first-in-class therapeutics. EDG-5506 is an orally administered skeletal myosin inhibitor in clinical trials in patients with Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a novel cardiac sarcomere modulator for the treatment of HCM and other disorders of cardiac diastolic dysfunction. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X (formerly Twitter), Facebook, Instagram and Threads. Edgewise Contacts Investors: Michael Carruthers, Chief Financial Officer [email protected] Media: Maureen Franco, VP Corporate Communications [email protected] Source: Edgewise Therapeutics Multimedia Files: Download: Download original 226 KB (2400 x 912) Download image: Multimedia file for Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference as a original in JPG format. Opens in a new window Download thumbnail 6 KB (200 x 76) Download image: Multimedia file for Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference as a thumbnail in JPG format. Opens in a new window Download lowres 17 KB (480 x 182) Download image: Multimedia file for Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference as a lowres in JPG format. Opens in a new window Download square 9 KB (250 x 250) Download image: Multimedia file for Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference as a square in JPG format. Opens in a new window View All News Quick Links SEC Filings Leadership Team Posters & Presentations IR Contact [email protected] Investor Email Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. Edgewise Therapeutics, Inc, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to Edgewise Therapeutics, Inc. to send you the requested Investor Email Alert updates. * Required Email Address * Investor Alert Options Investor Alert Options * News Events & Presentations Quarterly Reports SEC Filings End of Day Stock Quote Unsubscribe Email Alert Sign Up Confirmation Contact Us 1715 38th St, Boulder, CO 80301 720.262.7002 [email protected] www.edgewisetx.com Quick Links Company Science Disease Areas Patients & Families Powered By Q4 Inc. 5.187.1.9 (opens in new window) Follow us Contact Us Privacy Policy Terms of Use Cookie Preferences © 2025 Copyright. Edgewise Therapeutics. All Rights Reserved.

The release as fetched from its publisher. edgewisetx.com ↗